Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer

The use of neoadjuvant chemotherapy or radiation for borderline resectable pancreatic adenocarcinoma (BL‐PDAC) is increasing. However, the impact of neoadjuvant chemotherapy and radiation therapy on the outcome of BL‐PDAC remains to be elucidated. We performed a retrospective analysis of 93 consecut...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Shrestha, Bikram, Sun, Yifei, Faisal, Farzana, Kim, Victoria, Soares, Kevin, Blair, Alex, Herman, Joseph M., Narang, Amol, Dholakia, Avani S., Rosati, Lauren, Hacker‐Prietz, Amy, Chen, Linda, Laheru, Daniel A., De Jesus‐Acosta, Ana, Le, Dung T., Donehower, Ross, Azad, Nilofar, Diaz, Luis A., Murphy, Adrian, Lee, Valerie, Fishman, Elliot K., Hruban, Ralph H., Liang, Tingbo, Cameron, John L., Makary, Martin, Weiss, Matthew J., Ahuja, Nita, He, Jin, Wolfgang, Christopher L., Huang, Chiung‐Yu, Zheng, Lei
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5504321/
https://ncbi.nlm.nih.gov/pubmed/28639410
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1104
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados